Anti-NGF Antibody and Antigen-Binding Fragment Patent Grant

ChangeBridge: Patent Grants - Peptides (C07K)

Published April 7th, 2026

Detected April 7th, 2026

Summary

USPTO granted Patent US12595298B2 to XIYUAN ANJIAN MEDICINE (SHANGHAI) CO., LTD. for an anti-NGF antibody and its antigen-binding fragment, covering the preparation method and therapeutic applications for NGF-mediated diseases. The patent includes 6 claims and was filed on August 2, 2021.

View original document View source feed page

What changed

USPTO issued Patent US12595298B2 granting XIYUAN ANJIAN MEDICINE (SHANGHAI) CO., LTD. exclusive rights to an anti-NGF antibody composition, its antigen-binding fragment, and associated polynucleotides and vectors. The patent covers methods of preparation and therapeutic applications for treating NGF-mediated diseases and disorders.

For pharmaceutical and biotechnology companies developing nerve growth factor (NGF) targeting therapies, this patent establishes intellectual property barriers requiring careful freedom-to-operate analysis. Competitors pursuing similar anti-NGF antibody programs should evaluate potential licensing needs or design-around strategies. Research institutions and drug developers working in the pain management or neurodegenerative disease space should monitor this portfolio for competitive implications.

What to do next

Monitor patent portfolio for freedom-to-operate implications
Assess potential licensing opportunities for NGF antibody therapeutics
Review patent claims for R&D collaboration possibilities

Source document (simplified)

← USPTO Patent Grants

Anti-NGF antibody and antigen-binding fragment thereof, preparation method, and application thereof

Grant US12595298B2 Kind: B2 Apr 07, 2026

Assignee

XIYUAN ANJIAN MEDICINE (SHANGHAI) CO., LTD

Inventors

Xiaohui Yuan, Guoyong Wang, Yujiao Liu, Donghong Zheng

Abstract

Provided are an anti-NGF antibody or an antigen-binding fragment thereof, a preparation method and an application thereof. Also provided is an isolated polynucleotide encoding the anti-NGF antibody or the antigen-binding fragment thereof, as well as a vector containing the isolated polynucleotide. Also provided is use of the antibody or the antigen-binding fragment thereof of the present invention in preparing the medicament for the treatment of NGF-mediated diseases or disorders.